A phase II trial of irinotecan in hormone-refractory prostate cancer

@article{Reese1998API,
  title={A phase II trial of irinotecan in hormone-refractory prostate cancer},
  author={David M. Reese and Simon Tchekmedyian and Yvonne Chapman and Diane J Prager and Peter. J. Rosen},
  journal={Investigational New Drugs},
  year={1998},
  volume={16},
  pages={353-359}
}
Irinotecan is a DNA topoisomerase I inhibitor that has a wide spectrum of activity against human tumors in both preclinical and clinical studies. To evaluate the efficacy of irinotecan in hormone-refractory prostate cancer, we conducted a phase II study in 15 men with metastatic, PSA-progressive disease after primary androgen deprivation. Irinotecan was… CONTINUE READING